Program
Aprepitant
Also written as “aprepitant”, “MK0869, aprepitant” and “Aprepitant Injection”.
Its studies are mostly in Depressive Disorder, Major · Vomiting · Nausea · Postoperative Nausea and Vomiting · Pruritus, led by 7 companies.
Drug pageAprepitant: every studyMany companies study it; this page follows only the 27 they lead. All 128 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Merck | 210 open or running | phase 4since Sep 21, 2004 | May 2, 2002 | none ahead |
| CSPC Pharmaceutical Groupits history only | 11 open or running | phase 3since Jul 17, 2024 | Jul 17, 2024 | none ahead |
| Lahore Medical Research Center, LLPits history only | 10 open or running | phase 3since Feb 23, 2024 | Feb 23, 2024 | none ahead |
| LEO Pharmaits history only | 10 open or running | phase 2since Sep 18, 2013 | Sep 18, 2013 | none ahead |
| Nuformix Technologiesits history only | 10 open or running | phase 1since Mar 20, 2019 | Mar 20, 2019 | none ahead |
| Ono Pharmaceuticalits history only | 10 open or running | phase 2since Sep 13, 2005 | Sep 13, 2005 | none ahead |
| Qilu Pharmaceuticalits history only | 10 open or running | phase 3since Apr 10, 2025 | Apr 10, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Merck only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 2, 2002First studies: 6 phase 3 studies in Depressive Disorder, MajorFirst studyNCT00035295, NCT00035282, NCT00035048 and 3 more
- Jul 22, 2002Phase 3 study in Depressive Disorder, MajorNCT00042029 · 324 enrolled
- Nov 4, 20022 phase 3 studies in Depressive Disorder, MajorNCT00048607, NCT00048594
- Mar 31, 2004Phase 3 study in VomitingNCT00080444 · 50 enrolled
- Sep 21, 2004Phase 3 study in NauseaNCT00092196 · 820 enrolled
- Sep 21, 2004Phase 4 study in NauseaNCT00092183 · 866 enrolled
- Jun 14, 2006Phase 3 study in VomitingNCT00337727 · 848 enrolled
- Jan 6, 20092 phase 1 studiesNCT00818259, NCT00819039
- Jul 23, 2009Phase 1 study in VomitingNCT00945321 · 42 enrolled
- Jul 31, 2009Phase 3 study in VomitingNCT00952341 · 421 enrolled
- Oct 6, 2009Phase 1 study in VomitingNCT00990821 · 188 enrolled
- May 26, 2011Phase 3 study in VomitingNCT01362530 · 307 enrolled
- Jul 5, 2012Phase 4 study in NauseaNCT01636947 · 494 enrolled
- Nov 19, 2012Phase 2 study in Post-operative NauseaNCT01732458 · 229 enrolled
TargetBeta
“Neurokinin 1 receptor antagonist”ChEMBL 37, by rule
Other programs on TACR1
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| elinzanetantrule | Bayer | phase 3 | 24 |
| tradipitantrule | Vanda Pharmaceuticals | phase 3 | 19 |
| fosnetupitantrule | Helsinn Healthcare | phase 3 | 2 |
| HRS5580 | Jiangsu HengRui Medicine | phase 2 | 2 |
Studies
All 21 Merck leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT01732458Post-operative Nausea | 2 | Completed | Sep 26, 2016 | 229 |
| NCT01636947Nausea | 4 | Completed | Aug 4, 2014 | 494 |
| NCT01362530Vomiting | 3 | Completed | Mar 14, 2013 | 307 |
| NCT00990821Vomiting | 1 | Completed | Dec 2005 | 188 |
| NCT00952341Vomiting | 3 | Completed | Apr 4, 2010 | 421 |
| NCT00945321Vomiting | 1 | Completed | Mar 2009 | 42 |
| NCT00819039Postoperative Nausea and Vomiting · United States, Brazil, Mexico and more | 1 | Completed | Mar 12, 2013 | 98 |
| NCT00818259Vomiting | 1 | Terminated | Jan 20, 2014 | 92 |
| NCT00337727Vomiting | 3 | Completed | Oct 28, 2008 | 848 |
| NCT00092196Nausea | 3 | Completed | Dec 1, 2004 | 820 |
| NCT00092183Nausea | 4 | Completed | Dec 1, 2003 | 866 |
| NCT00080444Vomiting | 3 | Completed | Sep 2006 | 50 |
| NCT00048607Depressive Disorder, Major | 3 | Completed | Dec 31, 2003 | 600 |
| NCT00048594Depressive Disorder, Major | 3 | Completed | Dec 18, 2003 | 800 |
| NCT00042029Depressive Disorder, Major | 3 | Completed | Oct 3, 2003 | 324 |
| NCT00035295Depressive Disorder, Major | 3 | Completed | Dec 5, 2003 | 584 |
| NCT00035282Depressive Disorder, Major | 3 | Completed | Dec 2003 | 450 |
| NCT00035048Depressive Disorder, Major | 3 | Completed | Dec 29, 2003 | 540 |
| NCT00035009Depressive Disorder, Major | 3 | Completed | Dec 22, 2003 | 468 |
| NCT00034983Depressive Disorder, Major | 3 | Completed | Dec 29, 2003 | 900 |
| NCT00034944Depressive Disorder, Major | 3 | Completed | Dec 17, 2003 | 495 |
How it is read
Names in the registry
- “aprepitant”, 8 entries
- “Aprepitant”, 4 entries
- “MK0869, aprepitant”, 4 entries
- “Aprepitant Injection”, 2 entries
- “Aprepitant 125 mg”, 2 entries
Codes read as this program: MK0869.
Conditions, from the studies’ own filings
- Depressive Disorder, Major, 9 studies
- Vomiting, 7 studies
- Nausea, 4 studies
- Postoperative Nausea and Vomiting, 3 studies
- Pruritus, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.